Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2020-04-27 Regulatory Filings
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance responding to comments on an Amendment 1 to a Preliminary Proxy Statement on Schedule 14A filed by Zafgen, Inc. It discusses revisions to disclosures in the proxy statement and references Amendment No. 2 to the Preliminary Proxy Statement. The document is not the proxy statement itself but a correspondence related to it, addressing SEC staff comments. The document length is 3866 characters, which is relatively short and consistent with a regulatory correspondence rather than a full report. The content focuses on responses to SEC comments on a proxy statement filing, which is typical for Regulatory Filings (RNS). It is not a full proxy statement (PSI), nor an announcement of a report publication (RPA), nor a remuneration report (DEF 14A). Therefore, the best classification is Regulatory Filings (RNS).
2020-04-27 English
PRER14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically a preliminary proxy statement dated April 27, 2020, related to the 2020 annual meeting of stockholders of Zafgen, Inc. It discusses matters to be voted on at the meeting, including approval of stock issuance pursuant to a merger agreement, a reverse stock split, election of directors, and other corporate governance matters. The document is not a full annual report, earnings release, or financial statement, but rather materials sent to shareholders to provide information and request votes for the annual meeting. This matches the definition of a Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement of it.
2020-04-27 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 21, 2020, by Zafgen, Inc. The content focuses on a notice received from Nasdaq regarding the company's failure to meet the minimum bid price requirement for continued listing on the Nasdaq Global Market. It details the compliance period, potential transfer to Nasdaq Capital Market, and possible delisting if compliance is not regained. This is a regulatory announcement about the company's listing status, specifically a delisting notice. The document is not a full financial report, earnings release, or management discussion, but an official notice about potential delisting. Therefore, the appropriate classification is Delisting Announcement (DLST). The document length (5355 characters) supports it being a full notice rather than a brief announcement or certification.
2020-04-24 English
Regulatory Filings 2020
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, fiscal period dates, or document titles that would allow identification of a specific filing type. The text does not include any indication of being a report, announcement, certification, or any other recognizable financial or corporate filing document. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS).
2020-04-24 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC Division of Corporation Finance regarding a Preliminary Proxy Statement on Schedule 14A filed by Zafgen, Inc. The letter addresses specific comments on disclosures in the proxy statement and mentions filing an Amendment No. 1 to the Preliminary Proxy Statement. The document references Schedule 14A, which is used for proxy statements related to shareholder meetings and voting matters. The content focuses on clarifications and revisions to the proxy statement rather than the proxy statement itself or voting results. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a correspondence responding to SEC comments on a proxy statement filing, not the proxy statement or voting results themselves.
2020-04-10 English
PRER14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically a preliminary proxy statement dated April 10, 2020, related to the 2020 annual meeting of stockholders of Zafgen, Inc. It discusses proposals for stockholder approval including issuance of common stock pursuant to a merger agreement, a reverse stock split, election of directors, and advisory votes on executive compensation. The document is clearly a solicitation of shareholder votes and contains detailed information about the matters to be voted on at the annual meeting. It is not a full annual report, earnings release, or other financial report, but rather a proxy solicitation document. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is the proxy statement itself, not just an announcement of it.
2020-04-10 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.